Zum Inhalt springenZur Suche springen


Folgende Publikationen hat das Institut für Klinische Pharmazie und Pharmakotherapie bereits erstellt:


186. Sayyed SA, Sharkas AR, Ali Sherazi B, Dabidian A, Schwender H, Läer S. Development and Assessment of Innovative High-Fidelity Simulation Vaccination Course Integrating Emergency Cases for Pharmacy Undergraduates—A Randomized Controlled Study. Vaccines (2023)



185. Ali Sherazi B, Läer S, Krutisch S, Dabidian A, Schlottau S, Obarcanin E. Functions of mHealth Diabetes Apps That Enable the Provision of Pharmaceutical Care: Criteria Development and Evaluation of Popular Apps. International Journal of Environmental Research and Public Health (2022)


184. Chamberlain R, Windolf H, Burckhardt BB, Breitkreutz J, Fischer B. Embedding a Sensitive Liquid-Core Waveguide UV Detector into an HPLC-UV System for Simultaneous Quantification of Differently Dosed Active Ingredients during Drug Release. Pharmaceutics (2022)


183. Gangnus T, Bartel A, Burckhardt BB. Mass spectrometric study of variation in kinin peptide profiles in nasal fluids and plasma of adult healthy individuals. Journal of Translational Medicine (2022)


182. Marceau F, Rivard GE, Hébert J, Gauthier J, Bachelard H, Gangnus T, Burckhardt BB. Picomolar sensitivity analysis of multiple bradykinin-related peptides in the blood plasma of patients with hereditary angioedema in remission: a pilot study. Frontiers in Allergy (2022)



181. Gangnus T, Burckhardt BB. Reliable Measurement of Plasma Kinin Peptides: Importance of Preanalytical Variables. Research and Practice in Thrombosis and Haemostasis (2021)


180. Majid H, Bartel A, Burckhardt BB. Predictivity of Standardized and Controlled Permeation Studies: Ex vivo – In vitro – In vivo Correlation for Sublingual Absorption of Propranolol. European Journal of Pharmaceutics and Biopharmaceutics (2021)


179. Majid H, Puzik A, Maier T, Merk R, Bartel A, Müller HC, Burckhardt BB. Formulation development of sublingual cyclobenzaprine tablets empowered by standardized and physiologically relevant ex vivo permeation studies. Pharmaceutics (2021)


178. Gangnus T, Burckhardt BB. Stabilization of short-lived peptides of the kallikrein-kinin system in human plasma to facilitate use as promising biomarkers. Clinical Chemistry (2021)


177. Farahani S, Farahani I, Deters MA, Schwender H, Burckhardt BB, Läer S. Investigating two in-class strategies in a flipped classroom–like setting to teach pharmacy students’ blood pressure measurement skills. Healthcare (2021)

176. Kottke D, Burckhardt BB, Knaab T, Breitkreutz J, Fischer B. Development and Evaluation of a Composite Dosage Form Containing Desmopressin Acetate for Buccal Administration. International Journal of Pharmaceutics X (2021) 3 (10082)


175. Majid H, Puzik A, Maier T, Eberhard D, Bartel A, Müller HC, Burckhardt BB. Exploring the transmucosal permeability of cyclobenzaprine: A comparative preformulation by standardized and controlled ex vivo and in vitro permeation studies. International Journal of Pharmaceutics (2021) 601 (120574)


174. Farahani S, Farahani I, Burckhardt BB, Monser K, Läer S. The development of an educational video on blood pressure measurement for pharmacy students. Currents in Pharmacy Teaching and Learning

173. Knaab T, Held J, Burckhardt BB, Rubiano K, Okombo J, Yeo T, Mok S, Uhlemann AC, Lungerich B, Fischli C, de Carvalho L, Mordmüller B, Wittlin S, Fidock DA, Kurz T. 3-Hydroxy-propanamidines, a new class of orally active antimalarials targeting Plasmodium falciparum. Journal of Medicinal Chemistry (2021) 64 (6), pp. 2851-3492


172. Gangnus T, Burckhardt BB. Targeted LC-MS/MS platform for the comprehensive determination of peptides in the kallikrein-kinin system. Analytical and Bioanalytical Chemistry (2021)


171. Kottke D, Burckhardt BB, Breitkreutz J, Fischer B. Application and validation of a coaxial liquid core waveguide fluorescence detector for the permeation analysis of desmopressin acetate. Talanta (2021) 226 (122092)


170. Gangnus T, Burckhardt BB. Sensitive mass spectrometric determination of kinin-kallikrein system peptides in light of COVID-19. Scientific Reports (2021)



169. Farahani I, Farahani S, Deters MA, Schwender H, Läer S. Efficacy of an Objective Structured Clinical Examination Training Approach for Training Pharmacy Students in Diabetes Mellitus Counseling: A Randomized Controlled Trial. Pharmacy (2020) 8 (4), 229, pp. 1 - 21


168. Smeets NJL, Schreuder MF, Dalinghaus M, Male C, Lagler FB, Walsh J, Läer S, de Wildt SN. Pharmacology of enalapril in children: a review. Drug Discovery Today (2020) 25 (11), pp. 1957-1970


167. Burckhardt BB, Ciplea AM, Laven A, Ablonczy L, Klingmann I, Läer S, Kleine K, Dalinghaus M, Dukic M, Breur JMPJ, van der Meulen M, Swoboda V, Schwender H, Lagler FB. Simulation training to Improve Informed Consent and PK/PD Sampling in Pediatric Trials. Frontiers in Pharmacologie (2020)


166. Feickert M, Burckhardt BB. Mass spectrometric studies on the peptide integrity of substance P and related human tachykinins in human biofluids. Peptides (2020)


165. Farahani S, Farahani I, Burckhardt BB, Schwender H, Läer S. Self-Instruction Video Versus Face-to-Face Instruction of Pharmacy Students’ Skills in Blood Pressure Measurement. Pharmacy (2020)


164. Majid H, Bartel A, Burckhardt BB. Development, Validation and Standardization of Oromucosal Ex-vivo Permeation Studies for Implementation in Quality-controlled Environments. Journal of Pharmaceutical and Biomedical Analysis (2020)


163. Gangnus T, Burckhardt BB. on behalf of the CARS consortium. Low-volume LC-MS/MS method for the pharmacokinetic investigation of carvedilol, enalapril and their metabolites in whole blood and plasma: application to a paediatric clinical trial. Drug Testing and Analysis  (2020)


162. Burdman I, Burckhardt BB. Human prorenin determination by hybrid immunocapture LC-MS: A mixed-solvent-triggered digestion utilizing D-optimal design. Rapid Communication in Mass Spectrometry  (2020)


161. Feickert M, Burckhardt BB. Validated Mass Spectrometric Assay for the Quantification of Substance P and human Hemokinin-1 in Plasma Samples: A Design of Experiments concept for comprehensive Method Development. Journal of Pharmaceutical and Biomedical Analysis (2020)


160. Farahani I, Läer S, Farahani S, Schwender H, Laven A. Blended learning: Improving the diabetes mellitus counseling skills of German pharmacy students. Curr Pharm Teach Learn.(2020); 12(8):963-974


159. Eggers C, Hoetelmans R, Läer S. Zidovudine and lamivudine reach higher concentrations in ventricular than in lumbar human cerebrospinal fluid. AIDS (2020) 


158. Burdman I, Burckhardt BB. Prorenin and active renin levels in paediatrics: A bioanalytical review. Clinical Chemistry and Laboratory Medicine (2020)


157. Gangnus T, Burckhardt BB. Improving sensitivity for the targeted LC-MS/MS analysis of the peptide bradykinin using a design of experiments approach. Talanta (2020); 218(121134)


156. Kottke D, Majid H, Breitkreutz J, Burckhardt BB. Development and Evaluation of Mucoadhesive Buccal Dosage Forms of Lidocaine Hydrochloride By Ex-vivo Permeation Studies. International Journal of Pharmaceutics (2020)


155. Makowski N, Ciplea AM, Ali M, Burdman I, Bartel A, Burckhardt BB; LENA Consortium. A comprehensive quality control system suitable for academic research: application in a pediatric study. Bioanalysis (2020); 12(5):319-333


154. Feickert M, Burdman I, Makowski N, Ali M, Bartel A, Burckhardt BB; LENA consortium. A continued method performance monitoring approach for the determination of pediatric renin samples - application within a European clinical trial. Clin Chem Lab Med. (2020)



153. Süßenbach FK, Makowski N, Feickert M, Gangnus T, Tins J, Burckhardt BB, on behalf of the LENA consortium. A quality control system for ligand-binding assay of plasma renin activity: Proof-of-concept within a pharmacodynamic study. Journal of Pharmaceutical and Biomedical Analysis (2019) 181


152. Díez CC, Khalil F, Makowski N, Schwender H, Jovanovic I, Dalinghaus M, Walsh J, van der Meulen M, Bajcetic M, de Wildt SN, Läer S. Pharmacotherapy in paediatric heart failure: a Delphi process. Cardiology in the Young (2019) 29(7), pp. 869-876


151. Läer S. Pharmacokinetic and pharmacodynamic modelling in paediatric drug development with a focus on physiology-based pharmacokinetic simulations. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen (2019) 141-142, pp. 66-73.


150. Feickert M, Burckhardt BB. A design of experiments concept for the minimization of nonspecific peptide adsorption in the mass spectrometric determination of substance P and related hemokinin-1. Journal of Separation Science (2019)


149. Burdman I, Burckhardt BB. A concept to make low-abundance endogenous renin accessible to mass spectrometry: A multistep experimental design approach. J Chromatogr B Analyt Technol Biomed Life Sci. (2019) 1134-1135 (21856)


148. Süßenbach FK, Tins J, Burckhardt BB on behalf of the LENA consortium. Customisation and validation of a low-volume plasma renin activity immunoassay: Enabling of regulatory compliant determination in paediatric trials. Practical Laboratory Medicine (2019)


147. Faisal M, Cawello W, Burckhardt BB, de Hoon J, Läer S, LENA Consortium. Simultaneous Semi-Mechanistic Population Pharmacokinetic Modeling Analysis of Enalapril and Enalaprilat Serum and Urine Concentrations From Child appropriate Orodispersible Minitablets. Frontiers in Pediatrics (2019) 7(281), pp. 1-11


146. Ali M, Tins J, Burckhardt BB on behalf of the LENA consortium. Fit-for-Purpose quality control system in continuous bioanalysis during long-term pediatric studies. The AAPS Journal (2019) 21(94), pp. 1-11


145. Van Hecken A, Burckhardt BB, Khalil F, de Hoon J, Klingmann I, Herbots M, Läer S,  Lagler FB, Breitkreutz J. Relative Bioavailability of Enalapril Administered as Orodispersible Minitablets in Healthy Adults. Clin Pharmacol Drug Dev. 2020 Feb;9(2):203-213


144. Bajcetic M, de Wildt SN, Dalinghaus M, Breitkreutz J, Klingmann I, Lagler FB, Keatley-Clarke A, Breur JMPJ, Male C, Jovanovic I, Szatmárik A, Ablonczy L, Burckhardt BB, Cawello W, Kleine K, Obarcanin E, Spatenkova L, Swoboda V, van der Meulen M, Wagner P, Walsh J, Läer S. Orodispersible minitablets of enalapril for use in children with heart failure (LENA): Rationale and protocol for a multicentre pharmacokinetic bridging study and follow-up safety study. Contemporatory Clinical Trials Communications (2019) 15 (100393), pp. 1-8


143. Feickert M, Burckhardt BB. Substance P in cardiovascular diseases - A bioanalytical review. Clinica Chimica Acta (2019) 495, pp. 501-506


142. Makowski N, Burckhardt BB. Enabling insights into the maturation of the renin-angiotensin-aldosterone system in children—Development of a low-volume LC-MS assay for the simultaneous determination of aldosterone, its precursor, and main metabolite. Steroids (2019) 148 pp. 73-81


141. Süßenbach FK, Burckhardt BB. Levels of angiotensin peptides in healthy and cardiovascular/renal deseased paediatric population - an investigative review. Heart failure reviews (2019) 24(11), pp. 1-15


140. Faisal M, Cawello W, Burckhardt BB, Läer S. Model-dependent pharmacokinetic analysis of enalapril administered to healthy adults volunteers using orodispersible minitablets for use in pediatrics. PMC Journal (2019) 13 (PMC 6354687), pp. 481-490


139. Castro Díez C, Khalil F, Schwender H, Dalinghaus M, Jovanovic I, Makowski N, Male C, Bajcetic M, van der Meulen M, de Wildt SN, Ablonczy L, Szatmári A, Klingmann I, Walsh J, Läer S. Pharmacotherapeutic management of paediatric heart failure and ACE-I use patterns: a European survey. BMJ (2019) 3(1), pp. 1-12



138. Rau S, Obarcanin E, Yikilmaz Ö, Läer S. Nur die Spitze des Eisbergs. Medizinische Monatsschrift für Pharmazeuten MMP (2018) 41 (4), pp. 156 – 159


137. Rau S, Obarcanin E, Läer S. Austausch gefährdet Therapieerfolg. Medizinische Monatsschrift für Pharmazeuten MMP (2018) 41 (4), pp. 160 - 162


136. Gangnus T, Burckhardt BB. Potential and Limitations of Atrial Natriuretic Peptide as Biomarker in Pediatric Heart failure - A Comparative Review. frontiers in Pediatrics (2018)


135. Cawello W, Braun M, Andreas JO. Drug Delivery and Transport into the Central Circulation: An Example of Zero-Order In vivo Absorption of Rotigotine from a Transdermal Patch Formulation. Eur J Drug Metab Pharmacokinet (2018) 43(4), pp. 475-481


134. Ali M, Läer S, Burckhardt BB. LC-MS/MS method for screening of intoxication and drug adherence of angiotensin converting enzyme inhibitors in plasma. Bioanalysis 2018


133. Ciplea AM, Läer S, Burckhardt BB. A feasibility study prior to an international multicentre paediatric study to assess pharmacokinetic/pharmacodynamic sampling and sample preparation procedures, logistics and bioanalysis. Contemporary Clinical Trials Communications (2018) 12, pp. 32 - 39



132. Deters MA, Laven A, Castejon AM, Doucette WR, Ev LS, Krass I, Mehuys E,, Obarcanin E, Schwender H, Läer S. Effective interventions for diabetes patients by community pharmacists – a meta-analysis of pharmaceutical care components. The Annals of pharmacotherapy. Article first published online: September 26, 2017


131. Schaefer J, Burckhardt BB, Tins J, Bartel A, Laeer S. Validated low-volume immunoassay for the reliable determination of direct renin especially valuable fpr pediatric investigations. Journal of immunoassay and immunochemistry, 2017


130. Schaefer J, Burckhardt BB, Tins J, Bartel A, Laeer S. Validated low-volume aldosterone immunoassay tailored to GCLP-compliant investigations in small sample volumes.

Practical Laboratory Medicine, 2017


129. Obarcanin E, Deters MA, Nemitz V, Läer S. Pharmazeutische Betreuung von Jugendlichen mit Diabetes mellitus Typ 1. Medizinische Monatsschrift für Pharmazeuten MMP (2016) 39 (11), pp. 483 - 487


128. Deters MA, Läer S, Hasanbegovic S, Nemitz V, Müller P, Krüger M, Schwender H, Obarcanin E. Wie betreuen wir als Apotheker einen Jugendlichen mit Diabetes mellitus Typ 1 ? Medizinische Monatsschrift für Pharmazeuten MMP (2016) 39 (11), pp. 477 - 482


127. Rasool MF, Khalil F, Läer S. Optimizing the Clinical Use of Carvedilol in Liver Cirrhosis Using a Physiologically Based Pharmacokinetic Modeling Approach. European journal of drug metabolism and pharmacokinetics. 2016:1-14 (online first)

126. Rasool MF, Khalil F, Läer S. Predicting stereo-selective disposition of carvedilol in adult and pediatric chronic heart failure patients by incorporating pathophysiological changes in organ blood flows - A physiologically based pharmacokinetic approach. (Drug Metabolism and Disposition: DMD Fast Forward. Published on April 11th 2016, DOI: 10.1124/dmd.115.068858)


125. Rasool M, Khalil F, Läer S. Author's Reply to Zheng et al.: A Physiologically Based Pharmacokinetic Drug-Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood Flows. Clin Pharmacokinet. 2015 2015/12/09:1-3.

124. Burckhardt BB, Tins J, Ramusovic S, Läer S Proof-of-concept study in blood, urine and saliva utilizing child-appropriate assays for pharmacokinetic and pharmacodynamic investigations of aliskiren and enalapril in adults. Journal of Pediatric Pharmacology and Therapeutics (akzeptiert 14.05.2015)

123. Rasool MF, Khalil F, Läer S A Physiologically Based Pharmacokinetic Drug-Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood Flows. Clin Pharmacokinet. 2015 Mar 14.

122. Ehlers, Benjamin and Laeer, Stephanie (2015) Recommendations for Inpatient Pediatric CPOE/CDS Systems - A Systematic Review. BAOJ Pharm Sci 003. 2015 Mar 12.

121. Burckhardt BB, Läer S. Sample Preparation and Extraction in Small Sample Volumes Suitable for Paediatric Clinical Studies: Challenges, Advances and Experiences of a Bioanalytical HPLC-MS/MS Method Validation Using Enalapril and Enalaprilat. International Journal of Analytical Chemistry, Volume 2015, Article ID 796249, 11 pages

120. Obarcanin E, Krüger M, Müller P, Nemitz V, Schwender H, Hasanbegovic S, Kalajdzisalihovic S, Läer S. Pharmaceutical Care of Adolescents with Type 1 Diabetes Mellitus: A Randomized Controlled Trial. Int J Clin Pharm. (akzeptiert 04.02.2015)

119. Khalil F, Lüpken R, Läer S, Bernstein D. Innovative tools in the individualized medical therapy for children with heart muscle disease. Prog Pediatr Cardiol. (in press 2015)

118. Läer, S. Bedeutet Off-Label eigentlich auch Off-Knowledge? Kinder Spezial/ Kinderärztliche Praxis Nr. 51. 2015, 18-20.


117. Burckhardt BB, Tins J, Laeer S. Simultaneous quantitative and qualitative analysis of aliskiren, enalapril and its active metabolite enalaprilat in undiluted human urine utilizing LC-ESI-MS/MS. Biomedical Chromatography 2014 Dec;28(12):1679-91 (2014)

116. Burckhardt BB, Tins J, Laeer S. Liquid chromatography-tandem mass spectrometry method for determination of aliskiren in saliva and its application to a clinical trial with healthy volunteers. Journal of pharmaceutical and biomedical analysis 2014 Aug 5;96:118-26 (2014)

115. Laven A, Schaefer J, Laeer S. PHARMAGRIPS: structured pharmaceutical counseling in the self-medication of the common cold. A randomised controlled study (RCT). Med Monatsschr Pharm. 2014 Jun;37(6):209-20 (2014)

114. Khalil F, Läer S. Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug. AAPS J. 2014 Mar, 16(2):226-39. (2014)

113. Müller S, Jaffan L, Kloiber E, Läer S. Dextromethorphan Missbrauch bei Jugendlichen - Wie kann sich der Apotheker verhalten? Medizinische Monatszeitschrift für Pharmazeuten (MMP) 2014 Mar;37(3):95-100.German

112. Khalil F, Läer S. Modeling and Simulation to Support Neonatal Clinical Trials. Pediatric and Adolescent Medicine Basel, Karger, 2015, vol 18, pp 58-69

111. Allegaert K, Fanos V, van den Anker J, Läer S. Perinatal pharmacology. BioMed Research International 2014;2014:101620 (2014)


110. Ramusovic S, Läer S, Meibohm B, Lagler FB, Paul T. Pharmacokinetics of intravenous amiodarone in children. Arch Dis Child. 2013, 98(12):989-93 (2013)

109. Burckhardt BB, Ramusovic S, Tins J, Läer S. Determination of aliskiren in human serum quantities by HPLC-tandem mass spectroscopy appropriate for pediatric trials. Biomedical Chromatography, DOI:10.1002/bmc.2815 (2013)

108. Laven A, Läer S. Pharmacist´s  requirements for evidence-based self-medication guidelines. Med Monatsschr Pharm. 2013 Mar, 36(3):102-10 (2013)

107. Lüpken R, Laeer S. Frage-Antwort: Hustentropfen mit Alkoholbeimengung. Pädiat. Prax 80, 471-473 (2013)

106. Della Casa Alberighi O, Barrett JS, Läer S, Meibohm B. Response to "Physiologically based pharmacokinetic modeling at the extremes of age". Clin Pharmacol Ther. 93:149 doi: 10.1038/clpt.2012.200 (2013)


105. Ramusovic S, Laeer S. An integrated physiology-based model for the interaction of Raa system biomarkers with drugs. J Cardiovasc Pharmacol. (2012)

104. Ramusovic S, Thielking G, Läer S. Determination of enalapril and enalaprilat in small human serum quantities for pediatric trials by HPLC-tandem mass spectrometry. Biomed Chromatogr 26:697-702 (2012)

103. Barrett JS, Della Casa Alberighi O, Läer S, Meibohm B. Physiologically based pharmacokinetic (PBPK) modeling in children. Clin Pharmacol Ther. 2012, 92:40-49

102. Response to a letter: Della Casa Alberighi O, Barrett JS, Läer S, Meibohm B. Response to "Physiologically Based Pharmacokinetic (PBPK) Modeling at the Extremes of Age". Clin Pharmacol Ther (2012). 

101. Burckhardt B, Läer S. ADHS-Medikation - assoziiert mit schwerwiegenden unerwünschten kardiovaskulären Arzneimittelwirkungen bei Kindern, Jugendlichen und Erwachsenen? Arzneiverordnung in der Praxis, 39 (2012)

100. Ehlers B, Läer S. Erhöhtes kardiovaskuläres Risiko bei Einnahme von Vareniclin? - Eine neue Meta-Analyse relativiert vorherige Ergebnisse. Arzneiverordnung in der Praxis (2012)


99. Vogt W, Läer S. Treatment for pediatric low cardiac output syndrome: Results from the European survey EuLoCOS-Paed. Arch Dis Child, in press (2011).

98. Vogt W, Läer S. Prevention for pediatric low cardiac output syndrome: Results from the European survey EuLoCOS-Paed. Pediatric Anesthesia 2011 Jul 19 (Epub ahead of print).

97. Läer S. Pediatric Cardiovascular Drug Development and Research: Integration of Modeling Simulation as One Future Direction. J Cardiovasc Pharmacol. 2011 Jun 3 (Epub ahead of print).

96. Vogt W, Läer S. Drug use patterns for the prevention of paediatric low cardiac output syndrome in Europe. Intensive Care Med. 2011 Jun 7 (Epub ahead of print).

95. Dohna-Schwake C, Fiedler M, Gierenz N, Gerner P, Ballauf P, Breddemann A, Läer S, Baba H, Hoyer PF. Primary HHV 6 infection after liver transplantation with acute graft rejection and multiorgan failure: successful treatment with a 2.5 fold dose of cidofovir and reduction of immunosuppression. Pediatr Transplant 15:E126-129 (2011)

94. Khalil F, Läer S. Physiologically Based Pharmacokinetic Modeling: Methodology, Applications and Limitations with a Focus on Its Role in Pediatric Drug Development. J Biomed Biotechnol 2011:1-13 (2011)

93. Läer S. Pediatric Cardiovascular Drug Development and Research: Integration of Modeling Simulation as One Future Direction. J Cardiovasc Pharmacol 58:217-227 (2011). 

92. Läer S, Meibohm B. Study design and simulation approach. Handb Exp Pharmacol 205:125-148 (2011).

91. Jaffan L, Läer S. Unerwünschte Arzneimittelwirkungen bei Kindern. Therapeutische Umschau 68, 34-40 (2011).


90. Gorny M, Röhm S, Läer S, Morali N, Niehues T. Pharmacogenomic Adaption of Antiretroviral therapy: overcoming the failure of lopinavir in an African infant with CYP2D6 ultrarapid metabolism. Eur J Clin Pharmacol 66, 107-108 (2010).

89. Ramusovic S, Breitkreutz J, Läer S. Bosentan in der Pädiatrie. Pharm Unserer Zeit 39, 454-457 (2010). 

88. Gorny M, Läer S. Arzneimittel für Kinder außerhalb der Zulassung: Überblick über den Off-Label Gebrauch in Deutschland. Kinder-Spezial 38, 10-12 (2010). 

87. Dickschen K, Läer S. Naftidrofuryl (z. B. Dusodril R) bei Claudicatio intermittens? - Eine Meta-Analyse soll Klarheit bringen. Arzneiverordnung in der Praxis 37, 33-35 (2010). 

86. Jaffan L, Läer S. Halluzinationen nach zwölf Dextromethorphan-Kapseln. Deutsche Apothekerzeitung 150, 1908 – 1909 (2010).  PDF-File

85. Läer S, Hildebrand M. Klinische Arzneimittelentwicklung. Lehrbuch der Klinischen Pharmazie, Wissenschafltliche Verlagsgesellschaft mbH Stuttgart 3, 113-124 (2010).


84. Gergs U, Neumann J, Simm A, Silber RE, Remmers FO, Läer S. Phosphorylation of phospholamban and troponin I through 5-HT4-receptors in the isolated human atrium. Naunyn Schmiedebergs Arch Pharmacol 379, 349-59 (2009). 

83. Nir A, Lindinger A, Rauh M, Bar-Oz B, Läer S, Schwachtgen L, Koch A, Falkenberg J, Mir TS. NT-pro-B-type natriuretic peptide in ingants and children. Reference values based on combined data from 4 studies. Pediatr Cardiol 30,3-8 (2009).

82. Läer S, Meibohm B, Barrett J. The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. J Clin Pharmacol 49, 889-904 (2009)

81. Ott H, Läer S, Walter C, Lange L, Schuster A. Paracetamol-Therapie und Asthmarisiko: Time for a change? Pädiatrische Allergologie 12, 23-25 (2009)

80. Frobel AK, Hulpke-Wette M, Schmidt KG, Läer S. Beta blockers for congestive heart failure in children. Cochrane Database of Systematic Reviews 1, CD007037 (2009)

79. Schmidt D, Läer S. Wege aus der Depression-Wenn pharmakogenetische Besonderheiten eine antidepressive Therapie ins Leere laufen lassen. Deutsche Apothekerzeitung 149, 2944-2952 (2009). 

78. Jaffan L, Läer S. Geschmacksveränderungen als unerwünschte Wirkung vieler Arzneistoffe – nichts Genaues weiß man (noch) nicht. Arzneiverordnung in der Praxis 36, 120-122 (2009).

77. Schmidt D, Läer S. Wenn der Schmerz nicht nachlässt - Pharmakogenetische Besonderheiten können für erfolglose Schmerztherapie verantwortlich sein. Deutsche Apothekerzeitung 149, 1994 – 2005 (2009). 

76. Schmidt D, Läer S. Wenn die Blutgerinnung nicht zu hemmen ist – Polymorphismus des Gens der Vitamin-K-Epoxid-Reduktase entscheidet über den Therapieerfolg von Phenprocoumon. Deutsche Apothekerzeitung 149, 902 -911 (2009).

75. Vogt W, Frobel AK, Läer S. Particularities of pharmacotherapy in children. Is there a metamorphosis of "therapeutic orphans"? Pharm Unserer Zeit 38, 22-29 (2009).

74. Läer S, Breddemann A. Klinische Studien-Wissenschaftlich fundierte Arzneimittelforschung am Menschen.Online-Academy 1, 16-28 (2009).

73. Frobel AK, Läer S. Fentanyl-Pflaster - Gefahren bei der Anwendung. Arzneiverordnung in der Praxis 36, 37-40 (2009).

72. Frobel AK, Läer S. Welcher Betablocker ist für die Therapie von Kindern mit Herzinsuffizienz geeignet?  Cardio News 2009, 12. Jahrgang, S 46-7. (2009)


71. Breddemann A, Läer S. Wie können Computersimulationen die Arzneimitteltherapie bei Kindern unterstützen? Med Monatsschr Pharm 31, 429-433 (2008).

70. Breddemann A, Hsien L, Tot E, Läer S. Quantification of cidofovir in human serum by LC-MS/MS for children.  J Chromatogr B Analyt Technol Biomed Life Sci 861, 1-9 (2008).

69. Albers S, Meibohm B, Mir T, Läer S. Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure. Br J Clin Pharmacol 65, 511-522 (2008).

68. Hsien L, Breddemann A, Frobel AK, Heusch A, Schmidt KG, Läer S.  Off-label drug use among hospitalised children: identifying areas with the highest need for research. Pharm World Sci 30, 497-502 (2008).

67. Ramusovic S, Läer S. Quo vadis, Acomplia. Arzneiverordnung in der Praxis 35, 129-130 (2008).

66. Röhm S, Schmidt D, Läer S. Was wissen wir über Pharmakogenetik? Deutsche Apothekerzeitung 27, 62-67 (2008). 

65. Schmidt D, Läer S. Wenn Helicobacter pylori sich nicht ausrotten lässt – Cytochrom-P450-2C19-Ausstattung entscheidet über das Ansprechen einer Eradikationstherapie. Deutsche Apothekerzeitung 148, 5502 – 5508 (2008).

64. Vogt W, Läer S. Lifestyle-Intervention und Metformin zur Vermeidung von Gewichtszunahme unter atypischen Antipsychotika. Arzneiverordnung in der Praxis 35, 78-79 ( 2008).

63. Vogt W, Läer S. Gewichtszunahme als unerwünschte Wirkung vieler Arzneimittel. Arzneiverordnung in der Praxis 35, 78-80 (2008).

62. Breddemann A, Läer S. Colesevelam - ein neuer Gallensäuren-Komplexbildner mit LDL-senkender Wirkung.  Arzneiverordnung in der Praxis 35, 55-57 (2008).


61. Breddemann A, Läer S, Schmidt KG, Harjes M, Adam R, Ludwig A, Niehues T, Schneider DT. Case Report:  Severe Gastrointestinal Inflammation related to Persistent HHV-6B Infection in a 10-month-old Cancer Patient. HERPES 14, 41-44 (2007).

60. Schmidt D, Läer S. Wobenzym N - ist die Wirksamkeit wirklich nachgewiesen? Arzneiverordnung in der Praxis 34, 108-109 (2007).

59. Röhm S, Stürer A Pietsch J, Läer S. Dextromethorphan - ein harmloses Hustenmittel? Deutsche Apothekerzeitung 31, 42-47 (2007).

58. Röhm S, Läer S. Raloxifen ohne kardio-protektiven Effekt, es bietet aber Schutz vor Mammakarzinomen: Die Ergebnisse der RUTH-Studie. Arzneiverordnung in der Praxis 34, 49-50 (2007).

57. Frobel AK, Hsien L, Breddemann A, Läer S. Arzneimitteltherapie von Kindern soll sicherer werden. Deutsche Apothekerzeitung 5, 50-60 (2007).


56. Sumner ME, Albers s, Schmidt KG, Laws HJ, Läer S. Drug interactions of tracolimus. Med Monatsschr Pharm 29, 139-141 (2006).

55. Albers S, Mir TS, Haddad M, Läer S. N-terminal pro brain natriuretic peptide: normal ranges in the pediatric population ncluding method comparison and interlaboratory variability. Clin Chem Lab Med 44, 80-85 (2006).

54. Mir T, Haun C, Lilje C, Läer S, Weil J. Utility of N-terminal Brain Natriuretic peptide plasma concentrations in comparison to actate and troponin in children with congenital heart disease following open heart surgery. Pediatr Cardiol 27, 209-216 (2006).

53. Mir TS, Flato M, Falkenberg J, Haddad M, Budden, R Weil J, Albers S, Läer S. Plasma concentrations of N-terminal brain natriuretic peptide (N-BNP) in healthy children and adolescents: effect of age and gender. Pediatr Cardiol 27, 73-77 (2006). 

52. Frobel AK, Läer S. Besonderheiten der Pharmakotherapie bei Kindern Apothekenmagazin 24, 168-175 (2006).


51. Meibohm B, Läer S, Panetta JC, Barrett JS Population Pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J 7, 475-487 (2005). 

50. Elshoff JP, Läer S. In vitro microdialysis cell for blood free pharmacokinetic studies in humans. J Pharmacol Toxicol Meth 52, 51-259 (2005). 

49. Läer S, Elshoff JP, Meibohm B, Weil J, Mir TS, Zhang W, Hulpke-Wette M. Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. J Am Coll cardiol 46, 1322-1330 (2005). 

48. Mir TS, Falkenberg J, Friedrich B, Gottschalk U, Le TP, Läer S, Weil J. Levels of brain natriuretic peptide in children with right entricular overload due to congenital cardiac disease. Cardiol Young 15, 396-401 (2005). 

47. Albers A, Elshoff JP, Völker C, Richter A, Läer S. HPLC quantification of metoprolol with solid phase extraction for the drug monitoring of pediatric patients. Biomed Chromatogr 19, 202-207 (2005). 

46. Läer S. Könnte eine Selengabe statininduzierte Myopathien verhindern? Arzneiverordnung in der Praxis 32, 30 (2005). 

45. Läer S. Vergleich zwischem niedermolekularem und fraktionierten Heparin bei Patienten mit Lungenembolien. Arzneiverordnung in der Praxis 32, 22-23 (2005).


44. Kindermann M, Maack C, Schaller S, Finkler N, Läer S, Wuttke H, Böhm M. Inotropic response to catecholamine stimulation during and after abrupt withdrawal of β-blocker medication: Metoprolol versus Carvedilol. Circulation 109, 3182-3190 (2004). 

43. Mir TS, Läer S, Marohn S, Eiselt M, Weil J. Effect of carvedilol on heart rate corrected QT-duration and QT dispersion in pediatric patients with congestive heart failure. J Drug Invest 24, 9-15 (2004). 

42. Läer S. Therapie der akuten Venenthrombosen mit Fondaparinux im Vergleich zu niedermolekularen Heparinen. Arzneiverordnung in der Praxis 31, 76-77 (2004). 

41. Initiative Kinder in Klinischen Prüfungen, B.Mühlbauer. Unabhängige klinische Forschung im Kindesalter und die 12. AMG-Novelle Grundsätzlich möglich, aber faktisch nicht mehr durchführbar. Monatsschrift Kinderheilkunde 152, 321-325 (2004).


40. Mir TS, Laux R, Liedke B, Heinze C, Buelow H, Läer S, M, Weil J. Plasma concentrations of aminoterminal atrial natriuretic eptide (N-ANP) and aminoterminal pro brain natriuretic peptide (N-BNP) in healthy neonates: marked and rapid increase after birth. Pediatrics 112, 896-899 (2003). 

39. Kirchhof P, Degen H, Franz MR, Eckardt L, Fabritz L, Milberg P, Läer S, Neumann J. Breithardt G, Haverkamp W. Amiodarone-induced post-repolarization refractoriness suppresses induction of ventricular fibrillation. J Exp Pharm Ther 305, 257-263 (2003). 

38. Scholz H, Läer S, Behn F, Eiselt M, Mir TS, Weil J. Effects of the beta-adrenoceptor blocker carvedilol in children with myocardial failure. In: Cardiac remodelling and failure 2003; Eds. Singal PK, Dixon IMC, Kirshenbaum LA, Dhalla NS; Kluwer Academic Publishers, Boston 2003, 123-133. 

37. Läer S. Ulkuskomplikationen bei Patienten mit Arthritis unter Celecoxib im Vergleich zu einer Kombinationstherapie mit Dicofenac und Omeprazol. Arzneiverordnung in der Praxis 30, 19-20 (2003). 

36. Läer S. Grippe - Aktuelles zur Impfung, Therapie und Prophylaxe. Arzneiverordnung in der Praxis 30, 9-10 (2003). 

35. Läer S. Oseltamivir zur Therapie und Prophylaxe der "Grippe" - der zweite Neuraminidase-Hemmer. Arzneiverordnung in der Praxis 1, 23-24 (2003).


34. Mir TS, Marohn S, Läer S, Eiselt M, Grollmus O, Weil J. Plasma concentrations of Nterminal-pro brain natriuretic peptide in ontrol children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 110, e76 (2002). 

33. Läer S, Mir TS, Behn F, Eiselt M, Scholz H, Venzke A, Weil J. Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. Am Heart J 143, 916-922 (2002).


32. Läer S. Untersuchungen zur Therapie von Herzrhythmusstörungen und Herzinsuffizienz bei Kindern. Habilitationsschrift, Fachbereich Medizin der Universität Hamburg (2001).  

31. Läer S, Meibohm B, Mir TS, Hulpke-Wette M. Termination of supraventricular tachycardia in an infant by adequate sotalol dosing: evidence for clinically relevant agedependent pharmacokinetics. Eur J Clin Pharmacol 57, 181-182 (2001). 

30. Behn F, Michels S, Läer S, Blaschke G. Separation of carvedilol enantiomers in very small volumes of human plasma by capillary electrophoresis with laser-induced fluorescence. J Chromatogr B 755, 111-117 (2001). 

29. Behn F, Läer S, Scholz H, Mir TS. HPLC quantification of carvedilol in small plasma samples from children. Chromatographia 53, 641-644 (2001). 

28. Läer S, Wauer I, Scholz H. Small blood volumes from children for quantitative sotalol determination using high-performance liquid chromatography. J Chromatogr B 753, 421-425 (2001) 

27. Läer S, Wauer I, Behn F, Scholz H, Mir TS, Weil J, Meibohm B, Hulpke-Wette M. Pharmacokinetics of sotalol in different age groups of children with tachycardia. J Pediatr Pharmacol Ther 6, 50-59 (2001).  

26. Behn F, Läer S, Scholz H. Determination of carvedilol in human cardiac tissue by highperformance liquid chromatography. J Chrom Sci 39, 121-124 (2001).  

25. Läer S, Scholz J, Ritterbach C, Läer C, Rahme E, Schulte am Esch J. Association between increased 5-HIAA plasma concentrations and postoperative nausea and vomiting (PONV) in patients undergoing general anaesthesia for surgery. Eur J Anaesthesiol 18, 833-838 (2001).  

24. Läer S. Vorbeugung von Lungenembolien und tiefen Beinvenenthrombosen mit niedrig dosierter ASS: die Pulmonary Embolism Prevention (PEP)-Studie. Arzneiverordnung in der Praxis 4, 21 (2001). 

23. Läer S. Häufigkeit schwerwiegender Komplikationen einer Acetylsalicylsäure-, Warfarinund intravenösen Heparintherapie zur Sekundärprohylaxe zerebraler Ereignisse. Arzneiverordnung in der Praxis 4, 20 (2001).


22. Mir TS, Eiselt M, Läer S, Marohn S, Venzke A, Weil. Chronische Herzinsuffzienz bei pädiatrischen Patienten - Erste klinische Erfahrungen in der zusätzlichen Therapie mit Carvedilol. Pädiatrie & Pädologie 6, 24-31 (2000). 

21. Lüss H, Meissner A, Rolf N, Van Aken H, Boknik P, Kirchhefer U, Knapp J, Läer S, Linck B, Lüss I, Müller FU, Neumann J, Schmitz W. On the biochemical mechanisms of stunning in the conscious dog. Am J Physiol Heart Circ Physiol 279, H176-H184 (2000). 

20. Läer S. Risiko von angeborenen Mißbildungen, Untergewicht oder Fehlgeburten durch die Verschreibung von Nichtsteroidalen Antirheumatika bei Schwangeren. Arzneiverordnung in der Praxis 2, 14 (2000).


19. Knapp J, Bokník P, Linck B, Läer S, Müller FU, Neumann J, Schlüter H, Zidek W, Schmitz W. Inositol-1, 4, 5-triphosphat increase by diadenosine tetraphosphate in preparation from failing human myocardium. Naunyn Schmiedebergs Arch Pharmacol 360, 354-357 (1999). 

18. Läer S. Natürliche und rekombinante Interferone. Medizinische Monatszeitschrift für Pharmazeuten (MMP) 11, 340-345 (1999). 

17. Läer S. Pharmakologie der Antiarrhythmika. Klinikarzt 3/28, 65-68 (1999).


16. Linck B, Bokník P, Baba HA, Eschenhagen T, Haverkamp U, Jäckel E, Jones LR, Kirchhefer U, Knapp J, Läer S, Müller FU, Schmitz W, Scholz H, Syska A, Vahlensiek U, Neumann J. Long term ß-adrenoceptor-mediated alteration in contractility and expression of phospholamban and SR-Ca2+-ATPase in mammalian ventricle. J Exp Pharm Ther 286, 531-538 (1998). 

15. Läer S, Scholz H, Buschmann I, Thoenes M, Meinertz T. Digitoxin intoxication during concomitant use of amiodarone. Eur J Clin Pharmacol 54, 95-96 (1998).  

14. Läer S, Remmers F, Stein S, Scholz H, Müller FU, Neumann J. Receptor mechanism involved in the 5-HT induced inotropic action in isolated rat atria. Br J Pharmacol 123, 1182-1188 (1998).  

13. Läer S. Rekombinante Interferone - Pharmakokinetik und Implikationen für die Therapie. Dtsch Med Wschr 123, 1320-1327 (1998).


12. Läer S, Scholz H, Uebeler P, Neumann J, Zimmermann N. Quantitation of diltiazem in human cardiac tissue using high-performance liquid chromatography. J Chrom Sci 35, 93-96 (1997). 

11. Läer S, Neumann J, Scholz H. Interaction between sotalol and an antacid preparation. Br J Clin Pharmacol 43, 269-272 (1997). 

10. Läer S, Apel M, Bernhardt J, Kapitulnik J, Kahl R. Interactions between bilirubin and reactive oxygen species in liver microsomes and in human neutrophil granulocytes. Redox Report 3, 119-124 (1997). 


9. Läer S, Neumann J, Scholz H, Uebeler P, Zimmermann N. Determination of sotalol in human cardiac tissue by high-performance liquid chromatography. J Chromatogr B 681, 291-298 (1996). 

8. Reymann A, Bunge A, Läer S, Dietel M. Morphological and functional features of cytostatic drug resistance and the effects of MDR modulators. Pharmazie 51, 171-175 (1996).  

7. Läer S, Bunge A, Dietel M, Meyer Pannwitt U, Schaefer A, Trapp M, Woermann C, Reymann A. Human leukemia cell lines K562-RADR express low levels of p-glycoproteinmediated multidrug resistence: Reference for clinical tumor specimen. In: Clinical Pharmacology and Oncology 1996; Eds. Kuhlmann J, Klotz U; Zuckschwerdt Verlag, München 1996, 68-72

6. Läer S, Bunge A, Dietel M, Meyer Pannwitt U, Schaefer A, Trapp M, Woermann C, Reymann A. Human leukemia cell lines K562-RADR express low levels of p-glycoproteinmediated multidrug resistence: Reference for clinical tumor specimen. In: Clinical Pharmacology and Oncology 1996; Eds. Kuhlmann J, Klotz U; Zuckschwerdt Verlag, München 1996, 68-72.


5. Steinfath M, Scholz J, Schulte am Esch J, Läer S, Reymann A, Scholz H. The technique of endobronchial lidocaine administration does not influence plasma concentration profiles and pharmakokinetic parameters in humans. Resuscitation 29, 55-62 (1995).


4. Läer S. Pharmakologische Beeinflussung des Dopaminstoffwechsels im Striatum der Ratte unter den Bedingungen zerebraler Oligämie. Inaugural-Dissertation, Medizinische Fakultät, Georg-August Universität Göttingen (1993).


3. Läer S, Huether G, Block F, Heim C, Sontag KH. Effect of transient reduction of cerebral blood flow in normotensive rats on striatal dopamine release. J Neural Transm 92, 203-211 (1992)

2. Sontag KH, Heim C, Block F, Sieklucka M, Schmidt-Kastner R, Melzacka M, Osborne N, Läer S, Huether G, Kunkel M, Ulrich F, Bortolotto Z, Weiner N, Wesemann U. Cerebral oligemic hypoxia and forebrain ischemia - common and different long-lasting consequences. In: Pharmacology of Cerebral Ischemia 1992; Eds. Krieglstein J, Oberpichler H; Wissenschaftliche Verlagsgesellschaft Stuttgart, Stuttgart 1992, 471-479.


1. Lampe H, Läer S, Wegener S. Klinikapotheker - Vision oder Wirklichkeit? Pharmazeutische Zeitung 4, 9-11(1990)